IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Centene Corp. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Centene Corporation ("Centene" or the "Company") (NYSE: CNC). Investors who purchased or otherwise acquired shares between April 26, 2016 and September 6, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the January 13, 2017 lead plaintiff motion deadline.

If you purchased shares of Centene during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that Centene made materially false and misleading statements concerning the acquisition of Health Net, Inc. on March 24, 2016, as well as failed to disclose: that certain Health Net insurance programs were significantly underperforming, which led to the need to increase reserves to offset losses caused by these programs; that Centene overstated the financial prospects of Health Net; and that as a result of the above, the Company's statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to learn more about this lawsuit at no charge, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161119005013/en/

Copyright Business Wire 2010

If you liked this article you might like

Why Centene Is One of Jim Cramer's 'Absolute Favorite Stocks'

Why Centene Is One of Jim Cramer's 'Absolute Favorite Stocks'

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

Jim Cramer: Breaking Down the State of the Union in Rhetoric Per Share

Jim Cramer: Breaking Down the State of the Union in Rhetoric Per Share